Printed from Voxsanity (voxsanity.com.au) — NCT06784206 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT06784206
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 18 and 75 years (any gender).
- People who have been diagnosed with limited-stage small cell lung cancer, confirmed through a tissue or cell sample test.
- People who have received no more than 2 cycles of standard chemotherapy before joining, or who have not yet had any cancer treatment.
- People with a general health and activity level rated as fully active or restricted in strenuous activity only (ECOG score of 0 or 1).
- People who have at least one measurable tumour that meets specific size requirements on a CT scan (confirm with trial site for exact measurements).
- People with an estimated life expectancy of at least three months.
- People who have adequate lung function (confirm with trial site for how this is assessed).
- People whose blood test results meet all of the following levels: haemoglobin at least 90 g/L; neutrophil count at least 1.5×10⁹/L; platelet count at least 100×10⁹/L; white blood cell count at least 3.0×10⁹/L.
- People whose organ function blood tests meet all of the following: albumin at least 30 g/L; liver enzymes (ALT and AST) below 3 times the upper limit of normal; total bilirubin no more than 1.5 times the upper limit of normal; creatinine (a measure of kidney function) no more than 1.5 times the upper limit of normal.
- People diagnosed with Gilbert's syndrome (a condition causing mildly elevated bilirubin) may still be considered eligible after discussion with the treating doctor.
- Women who could become pregnant must have a negative pregnancy test (blood or urine) within 7 days before enrolling, and both men and women of childbearing age must agree to use reliable contraception throughout the study and for 6 months after treatment ends.
- People who are willing to voluntarily join the study, sign a consent form, follow the study requirements, and attend follow-up appointments.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is a mixed type containing both small cell and non-small cell components.
- People with extensive-stage small cell lung cancer (meaning the cancer has spread more widely).
- People who have previously had an organ transplant or a bone marrow/stem cell transplant from a donor, or who are planning to have one.
- People who have taken certain immune-suppressing medications within 14 days before the first study treatment (this includes drugs such as prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, or anti-TNF drugs, but does not include nasal or inhaled steroids, or very low daily doses of steroids).
- People with a known allergy to etoposide, cisplatin, Adebrelimab, or related ingredients, or who have had a severe allergic reaction to another monoclonal antibody medication.
- People who have received a live attenuated vaccine within 4 weeks before the first dose, or who plan to receive one during the study.
- People who currently have, or have a history of, an active autoimmune disease (such as autoimmune hepatitis, lung inflammation, eye inflammation, bowel inflammation, thyroid conditions, vasculitis, or kidney inflammation), with exceptions for: people with vitiligo or hair loss (alopecia); and people with stable hypothyroidism well-controlled on hormone replacement therapy.
- People with asthma that is not well controlled with systemic treatment (people whose asthma fully resolved in childhood and requires no treatment as an adult may still be considered).
- People whose urine test shows significant protein levels (2+ or more on a dipstick test, or 1.0g or more confirmed over a 24-hour collection).
- People who have previously been diagnosed with another cancer, unless it was a fully treated skin cancer (basal or squamous cell) or cervical carcinoma in situ, or another cancer treated with the intent to cure with no known active disease for at least 5 years and a low risk of returning.
- People who are infected with HIV or have been diagnosed with AIDS.
- People who have experienced any of the following within the 6 months before enrolling: a heart attack, severe or unstable chest pain (angina), moderate-to-severe heart failure, poorly controlled irregular heartbeat (including specific abnormal readings on a heart tracing), or symptomatic congestive heart failure.
- People who have had an infection requiring intravenous antibiotics, antifungal, or antiviral treatment within 4 weeks before the first dose, or who have had an unexplained fever of 38.5°C or higher during the screening period.
- People with active tuberculosis, active hepatitis B (with virus levels above a specified threshold), active hepatitis C (with a positive antibody test and detectable virus), or a combined hepatitis B and C infection.
- People who have participated in another drug clinical trial within 4 weeks before the first dose.
- People with a known history of misusing psychoactive substances or drug addiction.
- People with other serious physical or mental health conditions, or significant abnormal test results, that the trial investigators consider would make participation unsafe or unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 139 0113 6511
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
1 August 2026
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Treatment-related adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.